Boston Scientific Corporation (NYSE:BSX) generated second-quarter revenues of $4.12 billion, beating the consensus estimate of $4.02 billion. Sales increased 14.5% on a reported basis, compared to the company’s guidance range of 10.5%-12.5% and 16.1% on an operational basis, 14.7% on an organic basis, compared to the company’s guidance range of 10%-12%. The company earned an adjusted EPS of $0.62, beating the consensus of $0.58 and the management guidance of ...